Redx Pharma PLC (AIM:REDX) chief executive Lisa Anson joined Proactive's Stephen Gunnion with details of the company's performance for the year ended 30 September 2021.
Anson telling Proactive that Rex made strong progress in advancing its pipeline. Its lead oncology asset, RXC004, entered a Phase 2 clinical trial and its lead fibrosis asset, RXC007, entered a Phase 1 clinical trial.
The company's discovery pipeline of differentiated programmes also continues to progress driven by the strength of its science and validated by milestone revenue increasing during the year, Anson added.